SIRIO Pharma opens multimillion gummy production plant18 Oct 2018
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.
Sirio Pharma has announced the opening of a gummy production plant at its new development and manufacturing facility in Ma’anshan (300 km West of Shanghai, China). This announcement comes 11 years after SIRIO opened its first gummy facility. The new site will be built in several phases and form a ‘Centre of Excellence’ covering an enormous 240,000 m2.
Phase Ⅰ of the site’s construction has just been completed and features a 26,000sqm gummy production plant and its associated building – designed to expedite development and manufacturing of gummy formulations for global customers.
“In the US and Europe in particular, there is a significant growth potential in gummy formulations – as they are seen as a more consumer-friendly dosage form. For many of the branded firms looking to enter this market early with customized formulations, we offer clear advantages. We can expedite development and even offer taste testing options during formulation. Alternatively, we also offer ready-to-go formulations for companies that are looking to enter the market quickly – because we have one of the largest ranges of existing gummy formulations of any global business. But as consumers become more discerning, we anticipate branded companies will increasingly need specialist gummy development partners and capabilities,” said Rui Yang, CSO of SIRIO Pharma.
The gummy production plant features integrated R&D and will increase production capacity to 2.4 billion gummies per year. SIRIO also expanded its ability to make innovative products such as liquid-filled, centre-filled, swirled and multicoloured gummies. In addition, SIRIO has hundreds of standard gummy formulation options suitable for market launch in the US and EU, and vegetarian options including carrageen and pectin, as well as sugar-free and low-sugar options.
“The advantage of running an integrated site is that we can develop a much more tailored product for customers, while also expediting development timelines, thanks to a large team of in-house gummy specialists - more than 10 scientists and formulation engineers dedicated to gummies. We anticipate exponential growth for the gummy lines in 2019. And obviously, with the new capacity we have, we can supply even for the largest of nutraceutical brands,” said Rui Yang, CSO of SIRIO Pharma.
Loren Israelsen, President, United Natural Products Alliance, on his recent visit to the new facility commented: “I have toured scores of dietary supplement factories around the world, but few equal Sirio's new gummy facility in terms of technology, state-of-the-art design and engineering, robotics, and R&D capabilities. This facility boasts world-class R&D and manufacturing and will help customers innovate new formulations for the fast-growing gummy market."
Chemspace and LabNetwork collaborate to extend access to chemical databases
14 Feb 2019
Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.Read more
SGS to conduct its first malaria human challenge trial in Belgium
13 Feb 2019
The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.Read more
New API screening program strengthens Particle Sciences' nanomilling offering
22 Jan 2019
Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.Read more
Preparing samples of cannabis plant for THC/CBD analysis
15 Jan 2019
Porvair Sciences has created a solid, stable and strong microplate that can withstand the applied forces in bead-beaters while maintaining a standard ANSI/SLAS footprint and key dimensions.Read more
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
WuXi AppTec expands site in California for pharmaceutical R&D services
13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.Read more
Cambrex expands analytical capabilities
12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.Read more
MIT engineers repurpose wasp venom as an antibiotic drug
9 Dec 2018
Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.Read more
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation